Protara Therapeutics Inc 2026年季度报告

TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements 2026 and 2025 (unaudited)3Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(unaudited)4 CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and aresubject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statementsreflect our current views with respect to, among other things, our operations and financial performance. All statements other thanstatements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. You can generallyidentify these forward-looking statements by terminology such as “believes,” “expects,” “potential,” “continues,” “may,” “will,”“should,” “seek,” “approximately,” “predict,” “intend,” “plans,” “estimates,” “anticipates” or the negative version of these terms or These forward-looking statements include, but are not limited to, statements about: ●estimates regarding our financial performance, including future revenue, expenses and capital requirements;●our expected cash position and ability to obtain financing in the future on satisfactory terms or at all;●expectations regarding our plans to research, develop and commercialize our current and future product candidates, includingTARA-002, and Intravenous, or IV, Choline Chloride;●expectations regarding the safety and efficacy of our product candidates;●expectations regarding the timing, costs and outcomes of our clinical trials; ●developments and projections relating to our competitors and industry; ●our ability to acquire, license and invest in businesses, technologies, product candidates and products; ●our ability to remain listed on the Nasdaq Global Market, or Nasdaq; ●the impact of and changes or developments in government laws and regulations, including any executive orders or tariffs; ●our ability to attract and retain key personnel to manage our business effectively; ●our ability to prevent system failures, data breaches or violations of data protection laws; ●the timing or likelihood of regulatory filings and approvals; ●our ability to protect our intellectual property position; and ●the impact of general U.S., foreign and global economic, industry, market, trade, regulatory, political or public healthconditions. More information on factors that could cause our actual results to differ from those expressed in forward-looking statements isincluded from time to time in our reports filed with the Securities and Exchange Commission, including in our Annual Report onForm10-Kfor the year ended December31, 2025, particularly under Part I, Item 1A, “Risk Factors.” Investors should understand that it isnot possible to predict or identify all such factors and should not consider the risks described above and under Part I, Item 1A, “RiskFactors” of our Annual Report onForm 10-K to be a complete statement of all potential risks and uncertainties. All forward-looking This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, ourbusiness, and the markets for certain medical conditions, including data regarding the estimated size of those markets, and theincidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market researchor similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events PART I – FINANCIAL INFORMATION PROTARA THERAPEUTICS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited)(in thousands, except share and per share data) Protara Therapeutics, Inc. and SubsidiariesNotes to Unaudited Condensed Consolidated Financial Statements(amounts in thousands, except share and per share data) 1. Organization and Nature of the Business Overview Protara Therapeutics, Inc., and its consolidated subsidiaries, or Protara or the Company, is a clinical-stage biopharmaceuticalcompany committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includestwo development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscleinvasive bladder cancer, or NMIBC, and lymphatic malformations, or LMs. Additionally, the Company’s portfolio includes Liquidity and Capital Resources The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company hasincurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in orde